ADMINISTRATIVE CORE Principal Investigator Matthew M. LaVail, Ph.D. is an internationally known senior vision scientist who has used many different types of research approaches, including anatomical, biochemical, classical genetic, molecular genetic and electrophysiological methods, as well as animal model development and neurotrophic factor and gene therapy studies for retinal degenerative diseases. His discoveries of circadian rod outer- segment disk shedding and the pharmaceutical rescue of degenerating photoreceptors have led to the establishment of new fields of vision research. He is highly respected at UCSF and in the vision research community. Dr. LaVail has been funded continuously by the NEI for the past 35 or more years with 6 different co-operative agreements, contracts and long-running research grants, so he is fully aware of both the research needs and regulations involved with NIH grants. Also, he has been an active member of the Core Grant Core Directors'Advisory Committee (see below), serving as the Imaging Core's first Director beginning in 1998. Through his leadership and effort in designing and constructing the Core, the Imaging Core has been the most heavily used of our Cores. Dr. LaVail distinguished himself, as well, in establishing procedures that would assure equitable access to the Core, even with very high usage at several times during the year just prior to several research meetings. One year before the retirement of the former Principal Investigator, Dr. Steven Kramer, Dr. LaVail was approved by the NE I to become the new Principal Investigator of the Core Grant effective July 1, 2002. We will use this process in case a Core Director or PI moves, retires or becomes unable to carry out the duties of the position, in which case the person will be identified by the Advisory Committee (see below), and the name will be submitted to the NEI for approval.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Center Core Grants (P30)
Project #
2P30EY002162-36A1
Application #
8884977
Study Section
Special Emphasis Panel (ZEY1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
36
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Biswas, Pooja; Naeem, Muhammad Asif; Ali, Muhammad Hassaan et al. (2018) Whole-Exome Sequencing Identifies Novel Variants that Co-segregates with Autosomal Recessive Retinal Degeneration in a Pakistani Pedigree. Adv Exp Med Biol 1074:219-228
Stryker, Michael P; Löwel, Siegrid (2018) Amblyopia: New molecular/pharmacological and environmental approaches. Vis Neurosci 35:E018
Nachury, Maxence V (2018) The molecular machines that traffic signaling receptors into and out of cilia. Curr Opin Cell Biol 51:124-131
Kim, Jean; Kudisch, Max; da Silva, Nina Rosa Konichi et al. (2018) Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. J Control Release 269:45-51
Afshar, Armin R; Damato, Bertil E; Stewart, Jay M et al. (2018) Re: Reddy et al.: Vitrectomy and vitrector port needle biopsy of choroidal melanoma for gene expression profile testing immediately before brachytherapy. (Ophthalmology. 2017;124:1377-1382). Ophthalmology 125:e28-e29
Feinstein, Max; Moussa, Kareem; Han, Ying (2018) Ab Interno Tube Occlusion for Postoperative Hypotony in a Patient With an Ahmed Glaucoma Drainage Device. J Glaucoma 27:e61-e63
Chansangpetch, Sunee; Nguyen, Anwell; Mora, Marta et al. (2018) Agreement of Anterior Segment Parameters Obtained From Swept-Source Fourier-Domain and Time-Domain Anterior Segment Optical Coherence Tomography. Invest Ophthalmol Vis Sci 59:1554-1561
Lew, Young Ju; Rinella, Nicholas; Qin, Jia et al. (2018) High-resolution Imaging in Male Germ Cell-Associated Kinase (MAK)-related Retinal Degeneration. Am J Ophthalmol 185:32-42
Lu, Jianmin; Luo, Lingyu; Huang, Deqiang et al. (2018) Photoreceptor Protection by Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF). eNeuro 5:
Lamy, Ricardo; Chan, Elliot; Lee, On-Tat et al. (2018) 880 kHz ultrasound treatment for drug delivery to the vitreous humor. Am J Transl Res 10:3162-3170

Showing the most recent 10 out of 581 publications